Jan Volavka mostly deals with Psychiatry, Schizophrenia, Internal medicine, Clinical psychology and Psychosis. The study incorporates disciplines such as Cohort study and Psychopathy in addition to Psychiatry. His Schizophrenia research integrates issues from Anesthesia and Pharmacotherapy.
His Internal medicine study incorporates themes from Extrapyramidal symptoms and Endocrinology. His work on Psychopathology as part of general Clinical psychology research is frequently linked to Victimology, bridging the gap between disciplines. His study in Psychosis is interdisciplinary in nature, drawing from both Allele and Catechol-O-methyl transferase.
Psychiatry, Schizophrenia, Clinical psychology, Internal medicine and Antipsychotic are his primary areas of study. The Aggression and Olanzapine research Jan Volavka does as part of his general Psychiatry study is frequently linked to other disciplines of science, such as Injury prevention, Suicide prevention and Human factors and ergonomics, therefore creating a link between diverse domains of science. In his work, Dopamine antagonist is strongly intertwined with Risperidone, which is a subfield of Olanzapine.
His work carried out in the field of Schizophrenia brings together such families of science as Haloperidol and Psychosis. Psychosis is closely attributed to Catechol-O-methyl transferase in his work. His Clinical psychology research is multidisciplinary, relying on both Personality disorders and Psychopathy.
The scientist’s investigation covers issues in Psychiatry, Schizophrenia, Clinical psychology, Aggression and Antipsychotic. His work in the fields of Olanzapine and Mental illness overlaps with other areas such as Injury prevention. His biological study focuses on Clozapine.
His Clozapine research includes elements of Haloperidol and Akathisia. His work in the fields of Clinical psychology, such as Psychopathology and Conduct disorder, overlaps with other areas such as Antisocial personality disorder. The concepts of his Internal medicine study are interwoven with issues in Schizoaffective disorder, Anesthesia and Extrapyramidal symptoms.
His primary scientific interests are in Psychiatry, Schizophrenia, Olanzapine, Internal medicine and Meta-analysis. His research on Psychiatry frequently links to adjacent areas such as Odds ratio. His work deals with themes such as Personality disorders, Aggression and Clinical psychology, which intersect with Schizophrenia.
His biological study spans a wide range of topics, including Clozapine and Psychopathy. His Clozapine research is multidisciplinary, incorporating elements of Haloperidol, Psychopharmacology, Psychosis and Personality. His study in the field of Randomized controlled trial, Discontinuation and Adjunctive treatment is also linked to topics like Placebo-controlled study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes.
Robert M Bilder;Jan Volavka;Jan Volavka;Herbert M Lachman;Anthony A Grace.
Neuropsychopharmacology (2004)
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
Robert M. Bilder;Robert S. Goldman;Jan Volavka;Pal Czobor.
American Journal of Psychiatry (2002)
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Jean Pierre Lindenmayer;Pal Czobor;Jan Volavka;Leslie Citrome.
American Journal of Psychiatry (2003)
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder
Jan Volavka;Pal Czobor;Brian Sheitman;Jean Pierre Lindenmayer.
American Journal of Psychiatry (2002)
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
Jari Tiihonen;Kristian Wahlbeck;Jouko Lönnqvist;Timo Klaukka.
BMJ (2006)
Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia
Robert M. Bilder;Jan Volavka;Pál Czobor;Anil K. Malhotra.
Biological Psychiatry (2002)
Neurobiology of violence
Jan Volavka.
(1995)
Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.
Karl Verebey;Jan Volavka;Salvatore J. Mule;R. B. Resnick.
Clinical Pharmacology & Therapeutics (1976)
Mental disorder and violence: is there a relationship beyond substance use?
Richard Van Dorn;Jan Volavka;Norman Johnson.
Social Psychiatry and Psychiatric Epidemiology (2012)
Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder.
Herbert M. Lachman;Karen A. Nolan;Pavel Mohr;Takuya Saito.
American Journal of Psychiatry (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
New York Medical College
Columbia University
Columbia University
Augusta University
New York University
University of California, Los Angeles
Nathan Kline Institute for Psychiatric Research
Centre for Addiction and Mental Health
Karolinska Institute
Research Triangle Park Foundation
French Institute for Research in Computer Science and Automation - INRIA
Huawei Technologies (China)
Microsoft (United States)
University of Limerick
University of St Andrews
Indian Institute of Technology Delhi
Institute of Cancer Research
Cancer Research UK London Research Institute
Ludwig-Maximilians-Universität München
TU Wien
University of California, Los Angeles
Northeastern University
American Cancer Society
University of Manchester
National Institutes of Health
University of Maryland, College Park